Hi, today we are going to talk about Neogen and its current landscape.
Neogen is poised to receive increasing attention from the market as relevant events are taking place. The company reports today its earnings that are expected to show an EPS of $0.32 and a $110.82 million revenue, numbers that are feasible to be achieved or at least don't deeply affect the company shares, as Neogen has received approval from the AOAC Research Institute for its Solaris for Enterobacteriaceae (EBAC), which is designed to help prevent harmful bacteria from contaminating food, pet food, nutraceutical, pharmaceutical, and cosmetic products. News that certainly will help boost Neogen's profits and performance.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Neogen is poised to receive increasing attention from the market as relevant events are taking place. The company reports today its earnings that are expected to show an EPS of $0.32 and a $110.82 million revenue, numbers that are feasible to be achieved or at least don't deeply affect the company shares, as Neogen has received approval from the AOAC Research Institute for its Solaris for Enterobacteriaceae (EBAC), which is designed to help prevent harmful bacteria from contaminating food, pet food, nutraceutical, pharmaceutical, and cosmetic products. News that certainly will help boost Neogen's profits and performance.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.